Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Inclusion Criteria: * Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\>) 2 centimeters (cm) by standard local assessment technique； * Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0), locally advanced (T2-3, N2-3,M0 or T4a-c, any N, M0), or infl ammatory (T4d, any N,M0)； * Known hormone receptor status (estrogen receptor and/or progesterone receptor)； * HER2 positive (HER2+++ by IHC or ISH+). * Baseline left ventricular ejection fracture \>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan； * Normalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization; * Absolute value of neutrophils ≥ 1.5 × 109 / L; * Platelet ≥ 90×109 / L; * Hemoglobin ≥ 90g / L; * Serum creatinine≤ 1.5 times the upper limit of normal (ULN); * Serum total bilirubin≤1.5 times ULN (except for Gilbert syndrome); * Aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) ≤ 1.5-fold ULN; * International normalized ratio (INR), activated partial prothrombin time (APTT) ≤ 1.5 times ULN. * ECOG≤1； Exclusion Criteria: * Stage IV metastatic ; * Bilateral breast cancer; * Previous anti-cancer therapy or radiotherapy for any malignancy; * History of other malignancy within 5 years, except for appropriately-treated carcinoma in Cervical carcinoma in situ, basal cell carcinoma or squamous cell skin cancer; * Serious cardiac illness or medical condition; * HIV antibody positive; HCV antibody positive and HCV RNA positive; HBcAb or HBsAg positive, and HBV DNA positive; * Sensitivity to any of the study medications, any of the ingredients or excipients of these medications; * Known mental history had poor compliance; * Known to have drug abusers; * Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy; * Needed intravenous antibiotic treatment due to infection within 7 days before random enrollment; * Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or expected to perform major surgery during the trial period; * Premenopausal women (menopause is defined as non treatment induced menopause≥12 months) or without surgical sterilization (e.g., ovariectomy and / or uterus): refuse to take one or more effective contraceptive measures during treatment and at least 6 months after the last study treatment; blood pregnancy test is positive; pregnant or lactating women; Considered unsuitable for the study or may not be able to complete the trial due to other reasons.